According to a research report from CSC, Moderna's personalized tumor mRNA vaccine has achieved promising results in Phase III clinical trials, propelling the commercialization of mRNA-based tumor vaccines and gradually tapping into their vast market potential. When administered in tandem with Immune Checkpoint Inhibitors (ICIs), this vaccine holds the promise of transforming conventional tumor treatment paradigms. Personalized tumor vaccines boast superior efficacy, and while they come with a higher price tag, they offer considerable pricing leeway. Conversely, universal vaccines drive down costs through mass production, extending their benefits to a wider spectrum of patients. AI technology is set to enhance various stages of mRNA tumor vaccine R&D, fostering their continuous evolution. Presently, domestic R&D endeavors in tumor mRNA vaccines are intensifying to bridge the gap, with the potential to secure distinctive breakthroughs in the near future. Companies involved and those within the industrial chain are well-positioned to capitalize on these emerging growth prospects.